Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Chemomab Therapeutics Ltd.:
We consent to the use of our report dated February 20, 2023, with respect to the consolidated financial statements of Chemomab
Therapeutics Ltd., incorporated herein by reference and to the reference to our firm under the heading “Experts” in the prospectus.
|
/s/ Somekh Chaikin
|
|
Member Firm of KPMG International
|
Tel Aviv, Israel
March 21, 2023